Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 3 |
List of Tables | 3 | 1 |
List of Figures | 4 | 1 |
Report Guidance | 5 | 1 |
Clinical Trials by Region | 6 | 8 |
Clinical Trials and Average Enrollment by Country | 7 | 2 |
Top Five Countries Contributing to Clinical Trials in Asia-Pacific | 9 | 1 |
Top Five Countries Contributing to Clinical Trials in Europe | 10 | 1 |
Top Countries Contributing to Clinical Trials in North America | 11 | 1 |
Top Five Countries Contributing to Clinical Trials in Middle East and Africa | 12 | 1 |
Top Five Countries Contributing to Clinical Trials in Central and South America | 13 | 1 |
Clinical Trials by G7 Countries: Proportion of Parkinson's Disease to Central Nervous System Clinical Trials | 14 | 1 |
Clinical Trials by Phase in G7 Countries | 15 | 1 |
Clinical Trials in G7 Countries by Trial Status | 16 | 1 |
Clinical Trials by E7 Countries: Proportion of Parkinson's Disease to Central Nervous System Clinical Trials | 17 | 1 |
Clinical Trials by Phase in E7 Countries | 18 | 1 |
Clinical Trials in E7 Countries by Trial Status | 19 | 1 |
Clinical Trials by Phase | 20 | 2 |
In Progress Trials by Phase | 21 | 1 |
Clinical Trials by Trial Status | 22 | 1 |
Clinical Trials by End Point Status | 23 | 1 |
Subjects Recruited Over a Period of Time | 24 | 1 |
Clinical Trials by Sponsor Type | 25 | 1 |
Prominent Sponsors | 26 | 3 |
Top Companies Participating in Parkinson's Disease Therapeutics Clinical Trials | 27 | 2 |
Prominent Drugs | 29 | 1 |
Latest Clinical Trials News on Parkinson's Disease | 30 | 13 |
Sep 29, 2016: NeuroDerm Provides Updates on ND0612 Long-Term Safety Trial and Submission of Marketing Applications | 30 | 1 |
Sep 22, 2016: Anavex Life Sciences Drug Shows Efficacy to Support Potential Disease Modification in Parkinson s Disease | 30 | 1 |
Sep 20, 2016: Adamas Announces Results of EASE LID 3, a Pivotal Trial of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) in Parkinson Disease Patients at the 4th World Parkinson Congress | 31 | 1 |
Sep 19, 2016: Parkinsons disease: Prexton Therapeutics completes phase 1 clinical trial | 32 | 1 |
Sep 19, 2016: NeuroDerm to Present ND0612L Data at 4th World Parkinson Congress Demonstrating Ease of Use of Mini-Pump Delivery System | 32 | 1 |
Sep 19, 2016: NeuroDerm to Present ND0612H Data at 4th World Parkinson Congress | 33 | 1 |
Sep 12, 2016: Adamas Announces Two Data Presentations on ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) at the 4th World Parkinson Congress | 33 | 1 |
Sep 08, 2016: Diabetes drug focus of new clinical trial for Parkinson s disease | 34 | 1 |
Sep 07, 2016: Boost Vaccination Data Encourage Continued Development of AFFiRiS Therapeutic Parkinson's Disease Vaccine Against Alpha-Synuclein | 34 | 1 |
Aug 29, 2016: Cynapsus Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson s Disease | 35 | 1 |
Aug 25, 2016: NeuroDerm Initiates Patient Enrollment in a Phase III Trial of ND0612L for the Treatment of Parkinson's Disease | 35 | 1 |
Aug 19, 2016: The First Dosing of RQ-00000010 at Virginia Commonwealth University Initiated | 36 | 1 |
Aug 15, 2016: Cynapsus Announces Positive Opinion from Data and Safety Monitoring Board on Phase 3 Parkinson s Disease Clinical Study Allowing for At-Home Titration | 36 | 1 |
Aug 12, 2016: Cynapsus Announces Publication in the Journal Movement Disorders of Data for the Treatment of OFF Episodes in Patients with Parkinson's Disease | 37 | 1 |
Aug 09, 2016: Voyager Therapeutics Initiates Third Cohort in Ongoing Phase 1b Clinical Trial of VY-AADC01 in Advanced Parkinson s Disease | 38 | 1 |
Jul 28, 2016: International Stem Cell Announces Successful Cell Transplantation for the First Patient in Phase 1 Clinical Trial of ISC-hpNSC | 38 | 1 |
Jul 26, 2016: NeuroDerm Announces Start of Bioequivalence Trial in Healthy Volunteers of ND0701, a New Continuous Subcutaneously Delivered Apomorphine Product Candidate for the Treatment of Advanced Parkinson Disease | 39 | 1 |
Jul 18, 2016: Cynapsus Therapeutics Provides European Clinical Update for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease | 39 | 1 |
Jul 18, 2016: Cynapsus Therapeutics Announces Positive Phase 3 Dose Titration Phase Results with APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease | 40 | 1 |
Jul 12, 2016: Leukemia drug shows early promise for treating Parkinsons disease and dementia | 41 | 1 |
Jul 07, 2016: Parkinsons UK &MedGenesis Therapeutix announce top-line results of Phase 2 GDNF safety and efficacy clinical trial | 42 | 1 |
Clinical Trial Profile Snapshots | 43 | 712 |
Appendix | 755 | 4 |
Abbreviations | 755 | 1 |
Definitions | 755 | 1 |
Research Methodology | 756 | 1 |
Secondary Research | 756 | 1 |
About GlobalData | 757 | 1 |
Contact Us | 757 | 1 |
Disclaimer | 757 | 1 |
Source | 758 | 1 |